Cancer Vaccine: Groundbreaking Trial Reported By This Biotech Company

Evaxion Biotech Breaks New Ground with Encouraging Phase 2 Clinical Data on EVX-01.

The Danish biotech company, Evaxion Biotech (NASDAQ: EVAX), has announced promising initial results from the Phase 2 clinical trials of its personalized cancer vaccine, EVX-01.

The recent reports by BioSpace and Yahoo Finance provide a detailed rundown of this significant advancement in the field of cancer immunotherapy.

EVX-01, developed by Evaxion, is a…